{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:50:50Z","timestamp":1753923050869,"version":"3.37.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"DOI":"10.7759\/cureus.78845","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T12:12:56Z","timestamp":1739275976000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparative Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers in Hypertensive Patients With Chronic Kidney Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mouzafar A","family":"Mhmndar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taranpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iram","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Shehryar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moosa R","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Mairaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safiyyah M","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil Deep","family":"Kolanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anosha","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.949260","article-title":"Hypertension in chronic kidney disease: what lies behind the scene","volume":"13","author":"Ameer OZ","year":"2022","unstructured":"Ameer OZ. Hypertension in chronic kidney disease: what lies behind the scene. Front Pharmacol. 2022, 13:949260. 10.3389\/fphar.2022.949260","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2016_84","article-title":"Hypertension in chronic kidney disease","volume":"956","author":"Hamrahian SM","year":"2017","unstructured":"Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol. 2017, 956:307-25. 10.1007\/5584_2016_84","journal-title":"Adv Exp Med Biol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188975","article-title":"Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: a systematic review and meta-analysis","volume":"12","author":"Lin YC","year":"2017","unstructured":"Lin YC, Lin JW, Wu MS, Chen KC, Peng CC, Kang YN. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: a systematic review and meta-analysis. PLoS One. 2017, 12:e0188975. 10.1371\/journal.pone.0188975","journal-title":"PLoS One"},{"key":"ref4","article-title":"Physiology, Renin Angiotensin System","author":"Fountain JH","year":"2025","unstructured":"Fountain JH, Kaur J, Lappin SL. Physiology, Renin Angiotensin System. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1871","article-title":"Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an analysis of the placebo arm of EXSCEL","volume":"42","author":"Clegg LE","year":"2019","unstructured":"Clegg LE, Heerspink HJ, Penland RC, et al.. Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an analysis of the placebo arm of EXSCEL. Diabetes Care. 2019, 42:318-26. 10.2337\/dc18-1871","journal-title":"Diabetes Care"},{"key":"ref6","article-title":"Calcium Channel Blockers","author":"McKeever RG","year":"2025","unstructured":"McKeever RG, Patel P, Hamilton RJ. Calcium Channel Blockers. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2015.02.002","article-title":"Eligibility criteria in systematic reviews: a methodological review","volume":"52","author":"McCrae N","year":"2015","unstructured":"McCrae N, Blackstock M, Purssell E. Eligibility criteria in systematic reviews: a methodological review. Int J Nurs Stud. 2015, 52:1269-76. 10.1016\/j.ijnurstu.2015.02.002","journal-title":"Int J Nurs Stud"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari S","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, et al.. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022, 387:2021-32. 10.1056\/NEJMoa2210639","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.hipert.2023.11.005","article-title":"Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial","volume":"41","author":"Garc\u00eda-Prieto AM","year":"2024","unstructured":"Garc\u00eda-Prieto AM, Verdalles \u00da, de Jos\u00e9 AP, et al.. Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial. Hipertens Riesgo Vasc. 2024, 41:95-103. 10.1016\/j.hipert.2023.11.005","journal-title":"Hipertens Riesgo Vasc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01028-6","article-title":"The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial","volume":"45","author":"Yoo TH","year":"2022","unstructured":"Yoo TH, Hong SJ, Kim S, et al.. The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. Hypertens Res. 2022, 45:2008-17. 10.1038\/s41440-022-01028-6","journal-title":"Hypertens Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05045-4","article-title":"Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria","volume":"36","author":"Bryant CE","year":"2021","unstructured":"Bryant CE, Rajai A, Webb NJ, Hogg RJ. Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. Pediatr Nephrol. 2021, 36:3211-9. 10.1007\/s00467-021-05045-4","journal-title":"Pediatr Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057503","article-title":"Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD","volume":"12","author":"M\u00e5rup FH","year":"2022","unstructured":"M\u00e5rup FH, Peters CD, Christensen JH, Birn H. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD. BMJ Open. 2022, 12:e057503. 10.1136\/bmjopen-2021-057503","journal-title":"BMJ Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19312","article-title":"Effects of ramipril on biomarkers of endothelial dysfunction and inflammation in hypertensive children on maintenance hemodialysis: the SEARCH randomized placebo-controlled trial","volume":"79","author":"Ateya AM","year":"2022","unstructured":"Ateya AM, El Hakim I, Shahin SM, El Borolossy R, Kreutz R, Sabri NA. Effects of ramipril on biomarkers of endothelial dysfunction and inflammation in hypertensive children on maintenance hemodialysis: the SEARCH randomized placebo-controlled trial. Hypertension. 2022, 79:1856-65. 10.1161\/HYPERTENSIONAHA.122.19312","journal-title":"Hypertension"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028322","article-title":"Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: a randomized controlled trial","volume":"100","author":"Youssef AM","year":"2021","unstructured":"Youssef AM, Elghoneimy HA, Helmy MW, Abdelazeem AM, El-Khodary NM. Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: a randomized controlled trial. Medicine (Baltimore). 2021, 100:e28322. 10.1097\/MD.0000000000028322","journal-title":"Medicine (Baltimore)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1982681","article-title":"Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase","volume":"37","author":"Jankauskiene A","year":"2021","unstructured":"Jankauskiene A, Drozdz D, Wasilewska A, et al.. Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase. Curr Med Res Opin. 2021, 37:2113-22. 10.1080\/03007995.2021.1982681","journal-title":"Curr Med Res Opin"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.638611","article-title":"Efficacy and safety of angiotensin-converting enzyme inhibitor in combination with angiotensin-receptor blocker in chronic kidney disease based on dose: a systematic review and meta-analysis","volume":"12","author":"Zhao M","year":"2021","unstructured":"Zhao M, Wang R, Yu Y, et al.. Efficacy and safety of angiotensin-converting enzyme inhibitor in combination with angiotensin-receptor blocker in chronic kidney disease based on dose: a systematic review and meta-analysis. Front Pharmacol. 2021, 12:638611. 10.3389\/fphar.2021.638611","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.031","article-title":"Comparative superiority of ACE inhibitors over angiotensin receptor blockers for people with CKD: does It matter?","volume":"67","author":"Mavridis D","year":"2016","unstructured":"Mavridis D, Palmer SC, Strippoli GF. Comparative superiority of ACE inhibitors over angiotensin receptor blockers for people with CKD: does It matter?. Am J Kidney Dis. 2016, 67:713-5. 10.1053\/j.ajkd.2016.02.031","journal-title":"Am J Kidney Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3236","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: a systematic review and retrospective individual participant-level meta-analysis of clinical trials","volume":"177","author":"Ku E","year":"2024","unstructured":"Ku E, Inker LA, Tighiouart H, et al.. Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: a systematic review and retrospective individual participant-level meta-analysis of clinical trials. Ann Intern Med. 2024, 177:953-63. 10.7326\/M23-3236","journal-title":"Ann Intern Med"},{"key":"ref21","article-title":"Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results","volume":"15","author":"Baltatzi M","year":"2011","unstructured":"Baltatzi M, Savopoulos C, Hatzitolios A. Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results. Hippokratia. 2011, 15:27-32.","journal-title":"Hippokratia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-016-0165-4","article-title":"The different therapeutic choices with ARBs. Which one to give? When? Why?","volume":"16","author":"D\u00e9zsi CA","year":"2016","unstructured":"D\u00e9zsi CA. The different therapeutic choices with ARBs. Which one to give? When? Why?. Am J Cardiovasc Drugs. 2016, 16:255-66. 10.1007\/s40256-016-0165-4","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos PI","year":"2018","unstructured":"Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2018, 93:325-34. 10.1016\/j.kint.2017.08.038","journal-title":"Kidney Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.slast.2025.100243","article-title":"Harnessing NLP to investigate biomarker interactions and CVD risks in elderly chronic kidney disease patients","volume":"31","author":"Han H","year":"2025","unstructured":"Han H. Harnessing NLP to investigate biomarker interactions and CVD risks in elderly chronic kidney disease patients. SLAS Technol. 2025, 31:100243. 10.1016\/j.slast.2025.100243","journal-title":"SLAS Technol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/337338-comparative-efficacy-and-safety-of-angiotensin-converting-enzyme-inhibitors-angiotensin-receptor-blockers-and-calcium-channel-blockers-in-hypertensive-patients-with-chronic-kidney-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T12:12:58Z","timestamp":1739275978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/337338-comparative-efficacy-and-safety-of-angiotensin-converting-enzyme-inhibitors-angiotensin-receptor-blockers-and-calcium-channel-blockers-in-hypertensive-patients-with-chronic-kidney-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.78845","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}